Nobel Prize-Winning Team
Founded by a Stanford Professor of Structural Biology and Nobel Laureate, a Stanford M.D./Ph.D., and a Harvard Business School/UW Madison Engineer who came together through a shared vision of improving patient outcomes with innovative and early, non-invasive detection of biomarkers for cancer and neurological diseases.
VISION
To create and support broad market solutions for early cancer detection to save millions of lives
Our Technology:
· Low Cost
· Non-Invasive
· High Precision
· Big Data and AI Insights
MISSION
1. Identify breath biomarkers for the detection of diseases such as cancer and neurological conditions
2. Save millions of lives by using breath-based diagnostics combined with other biomarkers to diagnose early
3. Commercialize an inexpensive, non-invasive, annual health screen
GLOBAL HEALTH PROBLEM
-
18.1 million new cancer cases each year
-
9.5 million deaths each year
-
Over 1.7 million new US cases of cancer diagnosed annually in the United States over 600,000 die from the disease (2018 estimate)
-
The annual direct cost of cancer care is approximately $150Bn in the US alone and is much higher elsewhere in the world
-
Indirect costs due to loss of work are also over $100Bn
-
The number of cases and cost will increase due to the aging population
CENTRAL LAB APPROACH
-
Diagnose Early utilizes central labs to perform analysis
-
Point of care solutions do not allow a comprehensive analysis of highly complex biosamples, such as breath
-
Diagnose Early uses proprietary technology to collect and analyze samples in our central lab located in Northern California
SUPERIOR HEALTH TECH BUSINESS MODEL
-
Able to scale
-
CLIA, LDT approach – reducing regulatory hurdles
-
The company evolves from being a medical device company, into a diagnostics company, into a computational analytics company through its a well-managed roadmap